摘要
目的：比较阿立哌唑口崩片和利培酮口崩片治疗女性首发精神分裂症的疗效和安全性。方法：将100例符合ICD-10的女性首发精神分裂症患者随机分为两组,分别给予阿立哌唑口崩片与利培酮口崩片治疗6周。于治疗前和治疗后2、4、6周末采用阳性症状与阴性症状量表（PANSS）评定临床疗效,副反应症状量表（TESS）评定不良反应。结果：治疗6周后总有效率阿立哌唑组90%,利培酮组92%,两者相比疗效近似（P〉0.05）;两药引起的不良反应一般为轻度或中度,患者耐受性较好。结论：阿立哌唑口崩片和利培酮口崩片治疗女性首发精神分裂症均有较好疗效,疗效相当,不良反应较小。
Objective ：To compare efficacy and safety of aripiprazol e orally disintegrating tablets and risperidnne orally disintegrating tablets in the treatment of female first -episode schizophrenia. Methods：100 patients with female first -episode schizophrenia by ICD - 10 were randomly allocated to two groups treated with aripiprazole orally disintegrating tablets or risperidone orally disintegrating tablets for 6 weeks. The Positive and Negative Syndromes Scale （PANSS） and Treatment Emergent Symptoms Scale （TESS） were used to evaluate efficacy and adverse effects respectively before and at the end of 2, 4, 6 weeks of treatment. Results ： The total effective rates for the aripiprazole and risperidone groups were 90% and 92% respectively after 8 weeks. There was no significant difference between the two groups （P 〉 0.05 ）. side effects were not serious, and patients often had good torlerabil ity for them. Conclusions： The results suggest that aripiprazole orally disintegrating tablets is as risperidone orally disintegrating tablets effective as for the treatment of female first - episode schizophrenia and produces fewer side effects.
出处
《中国民康医学》
2009年第3期241-242,245,共3页
Medical Journal of Chinese People’s Health
关键词
阿立哌唑
利培酮
口崩片
女性首发精神分裂症
疗效
安全性
Aripiprazole
Risperidone
Orally Disintegrating Tablets
Female First- Episode Schizophrenia
Efficacy
Safety
